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Androgens and oestrogens have been implicated in prostatic carcinogenesis
and tumour progression. Although the actions of androgens have been
studied extensively, the mechanisms underlying oestrogen signalling in
prostate cancer are not fully understood. In the present study, we analyzed
the effect of androgens and oestrogens on the expression of anterior gradi-
ent 2 (AGR2) and anterior gradient 3 (AGR3), comprising two highly-
related genes encoding secretory proteins that are expressed in prostate
cancer and one of which (AGR2) has been associated with tumour metasta-
sis. Quantitative reverse-transcriptase PCR and western blot analysis
showed androgen induction of AGR2 and AGR3 in three androgen recep-
tor positive cell lines, starting at concentrations of 0.1 nM. Both AGR
genes were also transcriptionally activated by  5 nM oestradiol but not
by isotype selective or nonselective oestrogen receptor agonists in DUCaP
cells that harbour a high-level of wild-type androgen receptor. A functional
androgen receptor but not oestrogen receptor turned out to be required for
both androgen and oestrogen regulation. This pattern of androgen and
oestrogen regulation was confirmed in VCaP cells and was also observed
for FKBP5, a well-characterized androgen-regulated gene. Genome-wide
chromatin-immunoprecipitation studies coupled with deep sequencing iden-
tified androgen receptor binding sites localized in the distal promoter and
intron regions of the AGR2 and AGR3 genes, respectively. The androgen
responsiveness of these enhancers was verified by luciferase reporter gene
assays and site-directed mutagenesis analysis. Androgen treatment also
induced p300 and RNA Pol II recruitment to androgen receptor enhancers
of AGR2 and initiated local chromatin remodelling and the formation of
RNA Pol II-containing androgen receptor transcription complexes.
Abbreviations
AGR2, anterior gradient 2; AGR3, anterior gradient 3; AR, androgen receptor; ARE, androgen-responsive element; ChIP, chromatin-
immunoprecipitation; ChIP-seq, ChIP-coupled sequencing; ChIP-qPCR, ChIP-quantitative real-time PCR; E2, 17ß-oestradiol; ER, oestrogen
receptor; ICI, ICI 182 780; PCa, prostate cancer; PSA, prostate-specific antigen; qRT-PCR, quantitative reverse transcriptase-PCR; siRNA,
small interfering RNA; TSS, transcriptional start site.
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Introduction
Androgen receptor (AR) signalling plays an important
role in the development and overall function of normal
prostate tissue, and promotes the growth and survival
of prostate cancer (PCa) cells [1]. Therefore, treatment
of locally advanced, relapsed or metastasized PCa is
based on inhibiting AR transcriptional activity, pri-
marily through deprivation of androgen by chemical
castration or through antiandrogens. Despite initial
good responses being achieved in most patients, they
eventually develop castration-resistant prostate
tumours, in most cases retaining active but dysregulat-
ed AR signalling [2]. Understanding the downstream
effector molecules that are regulated directly or indi-
rectly by AR is thus important for unravelling the
molecular mechanisms of AR signalling in PCa devel-
opment and progression, as well as for providing ther-
apy targets or disease biomarkers.
The targets of AR include those essential for the
secretion function of the prostate, such as prostate-spe-
cific antigen (PSA) and KLK2, which are also the
best-studied androgen-regulated proteins [3,4]. Andro-
gens also regulate those molecules involved in prolifer-
ation and survival pathways that are crucial for
tumour development, such as cyclin-dependant kinases
2 and 4, P16 and caspase 2 [5,6]. One of the most sig-
nificant recent advances in the understanding of the
function of androgen in promoting PCa development
is the identification of the recurrent chromosomal
translocations that result in the androgen-driven
expression of fusion ETS (E-twenty six transformation
specific) transcription factors such as ERG [7].
Intriguingly, several known androgen-responsive
genes, such as the fusion gene for TMPRSS2-ERG, as
well as the genes for PSA, KLK2 and NKX3.1, were
also reported to be oestrogen-regulated either through
the oestrogen receptor (ER) [8] or through promiscu-
ous activation of mutated AR [9]. Anterior gradient 2
(AGR2) is one such protein whose expression has been
reported to be regulated by both androgens and oes-
trogens [10–12]. AGR2 is a protein disulfide isomerase
that is essential for the isomerization and maturation
of the intestinal mucin MUC2 [13]. It is overexpressed
in a variety of tumours, including prostate [10,12,
14,15] and breast tumours [11], and is associated with
prognosis [15]. AGR2 was found to be induced in oes-
trogen-treated normal breast tissue [16] and upregulat-
ed by oestradiol in MCF-7 and ZR-75-1 breast cancer
cells [11,15]. In the PCa cell line LNCaP, it is upregu-
lated by androgens and oestrogens, although less effi-
ciently by the latter steroid hormone [12]. The AGR2
transcript was found to be elevated in urine sediment
samples of PCa patients [10]. Its overexpression in
PCa cells leads not only to cell cycle arrest and inhibi-
tion of growth but also to an enhancement of migra-
tion [10]. The tumourigenic function of AGR2 is
associated with cell growth, survival and metastases
[11,15,17], as reviewed recently [18].
Compared to AGR2, much less is known about
anterior gradient 3 (AGR3), a protein with 71%
sequence similarity to AGR2, for which the gene is
located close to the AGR2 gene on chromosome 7p21
[17]. Similar to AGR2, it also has a predicted protein
disulfide isomerase function [19]. AGR3 was initially
identified in breast cancer cell membranes [20] and
found to be associated with ER positive breast
tumours [17]. It is also upregulated in some ovarian
cancers and was suggested as a tumour marker for
that cancer type [21, 22]. Little is known about the
hormone regulation of this protein in human tumours.
In the present study, we analyzed the steroid hor-
mone regulation of AGR2 and AGR3 in PCa cells,
especially their regulation via androgens and oestro-
gens. The main finding of the present study was the
characterization of both AGR genes as androgen-
responsive genes. AR binding sites within both genes
were identified using chromatin-immunoprecipitation-
coupled sequencing (ChIP-seq). The androgen respon-
siveness of these sequences was verified by luciferase
reporter gene assays and site-directed mutagenesis anal-
ysis. Androgen induced p300 and RNA Pol II recruit-
ment to the enhancers of AGR2, indicating local
chromatin remodelling, namely the formation of RNA
Pol II-containing AR transcriptional complexes bridg-
ing distal enhancers to the proximal promoter, which is
a model of androgen regulation that is also seen in the
gene for PSA [3]. In addition to androgen regulation,
17ß-oestradiol (E2) turned out to be the only oestrogen
among several isotype selective or nonselective agonists
that mediates the induction of the AGR genes and the
results of the present study show that this occurs via
promiscuous activation of the wild-type AR.
Results
Androgen regulation of AGR2 and AGR3
expression in PCa cells
Androgen treatment of PCa cell lines 22Rv1, LNCaP
and DUCaP confirmed the androgen regulation of
AGR2 expression (Fig. 1A) [10,12]. To investigate
whether its close homologue AGR3 is also androgen-
responsive, these AR+ PCa cell lines were incubated
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Fig. 1. Androgen and oestrogen regulation of AGR2 and AGR3 expression in PCa cells. Upregulation of AGR2 and AGR3 expression by
androgens and other steroid hormones was measured in AR positive PCa cell lines by real-time PCR and western blotting. (A) Prostate
cancer cells 22Rv1, LNCaP and DUCaP were treated with the synthetic androgen R1881 (1 nM) for 24 h or (B) for the times indicated and
the induction of AGR2 and AGR3 mRNAs was determined by real-time PCR. (C) The androgen dose–response on AGR2 and AGR3
transcript levels was measured in DUCaP cells after 24 h of incubation with the indicated doses of R1881. (D) Effect of 10 nM
concentrations of the non-androgen steroid hormones 17b-oestradiol (E2), progesterone (P4) and dexamethasone (Dex) on the expression of
AGR2 and AGR3 mRNA and AGR2 protein levels in DUCaP cells. (E) Time course and (F) concentration dependence regulation of AGR
genes by E2 in DUCaP cells. (G) AGR2 transcript and protein levels were measured in DUCaP cells after 24 h of treatment with the natural
ER agonist E2, the nonselective synthetic ER agonist diethylstilbestrol (DES), the ERa subtype-specific agonist 1,3,5-tris(4-hydrox-phenyl)-4-
propyl-1H-pyrazole (PPT) and the ERb subtype-specific agonist 2,3-bis(4-hydroxyphenyl)propionitrile (DPN). (H) AGR2 transcript and protein
levels were determined after 24 h of incubation with the ER antagonist ICI alone (control, C) or together with E2 (10 nM) or R1881 (1 nM) or
with the hormones alone. The mRNA of the oestrogen repressed gene IGFBP5 served as a control for the inhibitory effect of the ER
antagonist ICI. AGR2 and AGR3 mRNAs were determined by qRT-PCR using the primers listed in Table 2. The house-keeping gene HPRT1
transcript served as an internal control for mRNA quantification. GAPDH was used as a loading control for western blotting protein analysis.
Histograms represent the mean  SD transcript levels of two or three independent experiments. Western blots are representative of two
or three independent experiments. Statistical differences were calculated using Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
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with synthetic androgen R1881 for 24 h (Fig. 1A).
AGR3 was significantly upregulated after treatment in
all three cell lines, showing 8-, 18- and 165-fold induc-
tion in 22Rv1, LNCaP and DUCaP, respectively
(Fig. 1A). Despite strong androgen-mediated induc-
tion, the basal expression of AGR3 is low (approxi-
mately 1000-fold lower than AGR2). In comparison,
the relative basal AGR2 and AGR3 mRNA expression
levels are listed in Table 1 for a panel of five AR posi-
tive PCa cell lines.
The temporal dynamics of AGR3 induction was
examined in time course assays with 1 nM R1881 treat-
ment. Induced AGR3 expression was observed in all
three cell lines upon 4 h of androgen treatment
(Fig. 1B). In 22Rv1 and LNCaP cells, AGR3 induction
reached peak levels after 24 h (8- and 18-fold induction,
respectively; Fig. 1B). By contrast, AGR3 mRNA lev-
els peaked after 8 h of hormone treatment in DUCaP
cells (393-fold induction) with a sustained elevated
expression thereafter (165-fold at 24 h; Fig. 1B).
By contrast to LNCaP cells that express a promiscu-
ous, mutated AR, DUCaP cells express wild-type AR at
a high level [23], and both AGR2 and AGR3 were rap-
idly and robustly upregulated by androgen in these cells.
To focus on regulation by wild-type AR, DUCaP cells
were predominantly employed in subsequent experi-
ments. Of note, this cell line was isolated from a dura
metastasis of a PCa patient and represents tumours har-
bouring the fusion gene for TMPRSS2-ERG, which is a
gene rearrangement found in approximately 50% of all
prostate tumours. In dose–response assays, the highest
induction of both AGR2 and AGR3 expression was
observed at concentrations as low as 0.1 nM R1881
(13- and 5-fold, respectively; Fig. 1C); higher concentra-
tions of 1 and 10 nM showed no further increase. This
confirmed the androgen responsiveness of both AGR
genes, although the fold induction was lower compared
to the dynamics experiment. This probably reflects some
variance of cell culture conditions or the low basal level
of AGR3 expression. Collectively, these data indicate
that AGR2 and AGR3 are rapidly upregulated in
response to androgen, suggesting that both are primary
AR targets.
Oestrogen regulation of AGR2 and AGR3 in PCa
cells
AGR2 and AGR3 expression has been associated with
ER positive breast cancer [17]. We therefore investi-
gated whether AGR2 and AGR3 are regulated by oes-
trogen and other steroid hormones in DUCaP cells,
which also express very low a and higher b isoforms
of the ER (data not shown). Both AGR2 and AGR3
were significantly upregulated at the mRNA level by
10 nM E2 (9- and 31.5-fold, respectively) and, to a
lower extent, also by progesterone (two- and seven-
fold) but not by the synthetic glucocorticoid dexameth-
asone (10 nM; Fig. 1D). A similar finding was
observed for AGR2 at the protein level (Fig. 1D).
Similar to the rapid induction of AGR2 and AGR3
expression in response to androgen (Fig. 1B), AGR2
and AGR3 mRNA levels were induced after 4 h of E2
treatment with an induction of two- and six-fold,
respectively (Fig. 1E). However, although 0.1 nM
R1881 was sufficient to dramatically upregulate AGR2
and AGR3 expression (Fig. 1C), a 100-fold higher
concentration of E2 (10 nM) was required to induce
the expression of AGR2 and AGR3 (11- and 27-fold
respectively; Fig. 1F).
To determine which ER isotype(s) were responsible
for E2-mediated induction of AGR2 and AGR3,
DUCaP cells were incubated with isotype-specific or
nonselective synthetic ER agonists (Fig. 1G). Although
the natural ER agonist E2 strongly induced AGR2
expression at both the mRNA and protein levels,
Table 1. Basal level of AGR2 and 3 mRNA expressions in different
PCa cell lines normalized to the housekeeping gene TBP.
Cell line AGR2 (mean  SD) AGR3 (mean  SD)
22Rv1 0.41  0.07 0.0011  0.0002
LNCaP 1.48  0.36 0.0011  0.0005
DUCaP 16.56  3.83 0.0083  0.0033
VCaP 55.79  19.50 0.1435  0.0114
LAPC-4 0.49  0.10 0.0016  0.0007
Table 2. Real-time PCR primer sequences.































Probe: Fam-TCT TCA CTC
TTG GCT CCT GTG
CAC A-Tamra
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neither ER isotype selective (1,3,5-tris(4-hydrox-phe-
nyl)-4-propyl-1H-pyrazole as ERa agonist and 2,3-bis
(4-hydroxyphenyl)propionitrile as ERb agonist), nor a
nonselective synthetic agonist (diethylstilbestrol), mod-
ulated the expression of AGR2 (Fig. 1G). Moreover,
the nonselective ER antagonist ICI 182,780 (ICI)
could not attenuate E2-mediated expression of AGR2
at both mRNA and protein levels (Fig. 1H), although
this drug effectively blocked the effect of E2 on the
known oestrogen-repressed gene for insulin-like growth
factor-binding protein 5 (IGFBP5) [24]. Taken
together, these data suggest that E2-mediated upregu-
lation of AGR2 and AGR3 may be ER-independent.
AR-dependent androgen and oestrogen
regulation of AGR2 and AGR3
We hypothesized that E2-mediated expression of
AGR2 and AGR3 may occur via promiscuous activa-
tion of wild-type AR rather than ER activation. To
investigate this possibility, small interfering RNA (siR-
NA)-mediated knockdown of AR and AR inhibition
by the antiandrogens flutamide and bicalutamide was
employed. AR siRNA dramatically reduced AR pro-
tein levels as expected (Fig. 2A). Following AR knock-
down, androgen induction of AGR2 and AGR3
mRNAs was attenuated and androgen induction of
AGR2 protein was attenuated in DUCaP cells
(Fig. 2A). Similar findings were observed in LNCaP
cells (data not shown). Furthermore, the antiandrogen
flutamide attenuated the androgen induction of AGR2
protein, as well as AGR2 and AGR3 mRNAs, in a
dose-dependent manner in DUCaP cells (Fig. 2B).
Interestingly, androgen stimulation also significantly
decreased AR expression (Fig. 2A), which is consistent
with the findings of another study performed in VCaP
cells that showed downregulation of AR expression by
androgens through histone modification [25]. AR
knockdown or inhibition of AR transcriptional activity
by an antiandrogen also attenuated the E2-mediated
expression of AGR2 (Fig. 2C,D), supporting the
hypothesis that E2-induced expression is also mediated
via the AR. In the LNCaP cell line harbouring a
mutant, promiscuous AR, oestrogen activation of AR
has been described [26]. To exclude this possibility in
DUCaP cells, their AR was re-sequenced and a wild-
type sequence was confirmed.
To exclude the possibility that oestrogen induction
via the AR is a cell type-specific phenomenon, we also
investigated androgen and E2 induction of AGR2 and
AGR3 in wild-type AR expressing VCaP cells. This
also allowed an analysis of AGR3 protein regulation
because VCaP was the only cell line expressing signifi-
cant amounts of AGR3 protein among a panel of six
PCa cell lines (Fig. 2E). Both AGR2 and AGR3
mRNAs were induced by androgen and E2 and induc-
tion was blocked by the simultaneous addition of an
AR-blocking antiandrogen in VCaP cells (Fig. 2F).
The antiandrogen decreased androgen stimulation of
AGR3 mRNA from 6.8- to 1.7-fold and abolished oes-
trogen-induced expression from 2.6- to 1.0-fold. The
AGR3 protein levels showed the same pattern
(Fig. 2F).
The observed steroid hormone regulation pattern is
not restricted to AGR2 and AGR3. The well charac-
terized androgen-regulated gene FKBP5 [27] displayed
the same induction by androgen and oestrogen in both
cell lines DUCaP and VCaP, and an antiandrogen sig-
nificantly blocked induction by both steroid hormones
(Fig. 3A).
DUCaP cells express a very high level of endogenous
AR. To investigate whether this high AR level is
required for E2 regulation, the AR negative PC-3 PCa
cell line was transfected with an androgen-driven lucif-
erase reporter vector and increasing amounts of a wild-
type AR expression vector. A significant induction of
reporter gene activity was observed in cells transfected
with a low amount (0.01 lg) of AR and stimulated with
1 nM R1881 (1.8-fold, P = 0.02; Fig. 3B). E2 also signif-
icantly induced reporter gene activity but only in cells
treated with  5 nM E2 and with high exogenous AR
expression (0.25 lg of AR expression vector; induction
of 1.6- and 2.4-fold for 5 and 10 nM E2 treatment,
respectively). The AR level required for E2 induction is
similar to the level found in DUCaP cells and much
higher that in LNCaP cells (Fig. 3B). Collectively, these
results suggest that a high expression level of endoge-
nous wild-type AR in DUCaP cells is responsible for
E2-mediated stimulation of the expression of AGRs
and other AR responsive genes.
Identification of AR regulatory sequences within
AGR2 and AGR3 genomic regions
AGR2 and AGR3 are rapidly induced (within 4 h) by
R1881 in DUCaP cells, characterizing their respective
genes as immediate–early androgen-responsive. To
identify putative AR-binding sites and thus potential
androgen-responsive elements (AREs) within the pro-
moter regions of AGR2 and AGR3, DUCaP cells were
treated for 1 h with 1 nM R1881 and subjected to
ChIP-seq as an unbiased approach aiming to locate all
AR binding sites within the DUCaP genome. This
approach identified > 40 000 putative AR-binding sites
which were then annotated to the nearest genes.
Prominent binding sites within several classic primary
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androgen-responsive genes (e.g. the genes for PSA,
KLK2, FKBP5 and NKX3.1) confirmed that this
approach was successful.
As hypothesized, putative AR-binding sites were
identified in the AGR2 and AGR3 gene regions. Four
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Fig. 2. Androgen and oestrogen regulation of AGR2 and AGR3 is mediated through the AR. AR function for hormone regulation of AGR2
and AGR3 was investigated in DUCaP and VCaP cells using AR knockdown by siRNA (AR si) treatment or inhibition of AR transcriptional
activity with the antiandrogens flutamide (Flut) or bicalutamide. Antiandrogens were added 1 h before hormone stimulation. SiRNA
knockdown of AR was initiated 2 days before the start of hormone treatment and luciferase siRNA (Contr si) served as a control. (A–D)
Androgen receptor function was blocked by siRNA knockdown (A, C) or antiandrogen treatment (B, D) followed by treatment with androgen
(R1881, 1 or 0.1 nM; A, B) or with oestrogen or androgen (E2, 10 nM; R1881, 1 nM; C, D) for 24 h in DUCaP cells. Subsequently, cells were
harvested and AGR2 and AGR3 transcripts and AGR2 protein levels were analyzed using qRT-PCR and western blotting, respectively. The
house-keeping gene HPRT1 transcript served as an internal control for mRNA quantification. GAPDH was used as a loading control for
western blot protein analysis. (E) AGR3 expression in different PCa cell lines was analysed by western blotting and a-tubulin was used as a
loading control. (F) Androgen and oestrogen-regulated AGR3 protein and mRNA expression were analysed in VCaP cells. The cells were
stimulated by either 0.1 nM R1881 or 10 nM E2 together with (or without) antiandrogen (bicalutamide) pre-treatment. TBP transcript served
as an internal control for mRNA quantification. GAPDH was used as a loading control for western blotting analysis. Values in diagrams
represent the mean  SD of at least two independent experiments. Western blots are representative images. Statistical differences were
calculated using Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
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promoter region of AGR2 located 11, 5.5, 8 and 17 kb
upstream of the transcriptional start site (TSS) and
designated AGR2 S1–S4, respectively, according to the
signal intensity of the ChIP-seq (Fig. 4A). Unlike the
multiple AR binding sites of AGR2, only one strong
AR binding site was identified in AGR3 and desig-
nated AGR3 S1. It localized to the first intron 1 kb
downstream of the TSS (Fig. 4B). ChIP-PCR with
independent samples confirmed that AGR2 S1–S4 and
AGR3 S1 represented bona fide AR-binding loci
(Fig. 4C). Consistent with hormone stimulation experi-
ments, E2 treatment also induced AR loading onto all
AGR2 and AGR3 enhancers, as well as onto the well-
defined enhancer for the gene for PSA, which was
included as a control (Fig. 4C).
To investigate the dynamics over time of AR
recruitment to AGR2 and AGR3 enhancers, DUCaP
cells were treated for different durations with 1 nM
R1881 and subsequently subjected to ChIP-quantita-
tive real-time PCR (ChIP-qPCR). AR recruitment to
all five loci was rapid (5–10 min), reaching peak levels
after approximately 1 h of androgen stimulation and
declined after 16 h of treatment (Fig. 4D). Of the four
AR-binding sites in AGR2, AGR2 S1 and S2 demon-
strated the highest enrichment by ChIP-qPCR (97-
and 98-fold, respectively), which is consistent with
their high signal intensities in ChIP-seq analysis
(Fig. 4A). Enrichment of AGR3 S1 (28-fold) was lower
than that of AGR2 S1 and S2 and only comparable to
enrichment of AGR2 S3 (20-fold). AGR2 S4, which
exhibited the lowest signal intensities by ChIP-seq, also
showed the lowest enrichment of AR (six-fold).
AR-binding sites in AGR2 and AGR3 contain
functional androgen-responsive elements
We next investigated whether the AR-binding sites
within AGR2 and AGR3 contain functional AREs.
Accordingly, AGR2 S1–S4 and AGR3 S1 sequences
were inserted into a luciferase reporter vector upstream
of an SV40 minimal promoter. Relative to an empty
vector control, AGR2 S1–S4 or AGR3 S1 had no sig-
nificant effect on luciferase activity in the absence of
androgens but, in the presence of 1 nM R1881, a
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Fig. 3. AR-mediated oestrogen regulation of FKBP5 and androgen-responsive reporter gene expression in PCa cells with a high level of AR
protein. (A) Androgen and oestrogen regulation of FKBP5 was analysed in VCaP and DUCaP cells. Cells were pre-treated with antiandrogen
(bicalutamide) or mock control followed by stimulation with steroid hormones for 24 h for VCaP cells or 8 h for DUCaP cells. Subsequently,
cells were harvested for mRNA quantification using real-time PCR. TBP transcript served as an an internal control for mRNA quantification.
(B) AR-negative PC-3 PCa cells were grown in 24-well plates and transfected with the indicated amounts of the AR expression vector
PSG5-AR together with 0.25 lg of the androgen-responsive luciferase reporter vector ARE2-PGL3B. SV40 enhancer/promoter driven renilla
luciferase reporter vector PGL4.73 was used as a transfection control. PSG5 vector without an insert served as a filling vector to adjust for
equal amounts of plasmid DNA. One day after transfection, the cells were treated with the indicated concentrations of E2 or R1881 for 24 h
and subsequently processed for dual luciferase assays. The firefly luciferase activity was normalized to renilla luciferase activity and the
regulation of hormone-treated samples was calculated in relation to the solvent control (Contr)-treated samples. Values represent the
mean  SD of 2–4 independent experiments. Western blots are representative images of two independent experiments. Statistical
differences were calculated using Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
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Of the four AR binding sites within AGR2, AGR2 S1
induced the highest fold change in luciferase activity (5.6-
fold, P < 0.001) with AGR2 S2–S4 mediating weaker
responses, with an induction of 1.8-, 1.7- and 3.0-fold,
respectively (Fig. 5A). AGR3 S1 resulted in a 30-fold
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Fig. 4. Identification and verification of AR regulatory elements in AGR2 and AGR3 genes. AR binding sites within the AGR2 (A) and AGR3
(B) genes were identified by ChIP and subsequent sequencing of isolated DNA fragments. The panels from top to bottom represent (1) a
scheme of the AGR2 (A) or AGR3 (B), gene regions on chromosome 7 (7p21.3 and 7p21.1, respectively); (2) genomic sequence frequencies
of androgen stimulated anti-AR immunoprecipitated; and (3) control solvent-treated anti-AR immunoprecipitated DNAs. Genomic locations
are indicated on the x-axis and genomic sequence frequencies are shown on the y-axis. Four AR binding sites upstream of the AGR2
transcription start site were designated as AGR2 S1–S4 and one AR binding site of AGR3 was designated as AGR3 S1. (C, D) PCR and
qPCR with AR-precipitated samples were used to confirm the AR recruitment to ChIP-seq identified AGR2 and AGR3 binding sites. DUCaP
cells were stimulated with 1 nM R1881, 10 nM E2 or control solvent (C) for 1 h or treated with 1 nM R1881 for the duration axis in (D).
Subsequently, cross-linked chromatin was immunoprecipitated with an anti-AR antibody or an isotype IgG control antibody. The precipitated
DNAs were then subjected to either normal PCR amplification followed by electrophoresis in 2% agarose gel and visualization of the PCR
product by SYBR Green staining (C) or to qPCR for quantification of androgen stimulated AR enrichment to the binding sites relative to
control solvent-treated samples (D). The input was the total genomic DNA used for AR-ChIP and served as normalization control for the AR
precipitated DNA. The PSA enhancer fragment located 4 kB upstream of the PSA transcription start site served as a positive control (C).
Values in (D) represent the mean values of three or four independent experiments. The SDs are not shown for clarity, although they ranged
from 1 to 51 for AGR2 S1, 1 to 67 for AGR2 S2, 0 to 13 for AGR2 S3, 0 to 2 for AGR2 S4 and 1 to 17 for AGR3 S1.
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To localize the androgen-responsive elements within
these regulatory sites, the bioinformatics tools MATIN-
SPECTOR [28] and PROMO [29] were applied. Putative
AREs were found in all five AR-binding enhancers:
three in AGR3 S1, two in each of AGR2 S1 and AGR2
S3, and one in each of the other sequences. AREs in
AGR2 S1 and AGR3 S1, which mediated highest
androgen regulation in reporter gene analysis, were
chosen for site-directed mutagenesis to verify their
functional activity. In the AGR2 S1 sequence, inactiva-
tion of ARE2 but not of ARE1 abrogated androgen-
induced luciferase activity (Fig. 5B), indicating that
ARE2 was responsible for androgen stimulation. Of
the three AREs in the AGR3 S1 enhancer, ARE3 is
the most essential one for androgen regulation because
inactivation of this ARE abolished androgen induction
most significantly with an drop in induction from
14.6- to 1.7-fold.
To rule out a cell type-specific activity of the AR
enhancers driving AGR2 and AGR3 expression in
DUCaP cells, we confirmed their function in AR nega-
tive PC3 cells by exogenous expression of AR. In addi-
tion, we also confirmed E2 induction at high AR



















































































AGR2 S1 Mut AGR3 S1 Mut
AGR2 S1 ARE1: 5’- AGCACAggaTGCTGA -3’ AGR3 S1 ARE1: 5’- TGAGCTttgTGTTCC-3’,
AGR2 S1 ARE1M: 5’- AGCACAggaCACCGA -3’ AGR3 S1 ARE1M: 5’- TGAGCTttgTTTGTC -3’
AGR2 S1 ARE2: 5’- AGGACAagcTGATCC -3’ AGR3 S1 ARE2: 5’- CAACTGtccCTGTCC -3’
AGR2 S1 ARE2M: 5'- AGGACAagcCACTCC -3‘ AGR3 S1 ARE2M: 5'- CAACTGtccGTCGCC -3’
AGR3 S1 ARE3: 5’- AGTACAagaTGACCA -3’,
AGR3 S1 ARE3M: 5'- AGTCTCagaTGACCA -3’
Fig. 5. Functional verification of AR
regulatory sequences identified in the AGR
genes. Identified AR-binding DNA
fragments were amplified by PCR and
cloned upstream of the SV40 promoter
into the enhancer site of the PGL3P firefly
luciferase reporter vector as described in
the Experimental procedures. Putative
AREs in the binding sites AGR2 S1–S4
and AGR3 S1 were identified by in silico
analysis. (A) Vectors harbouring the AR
binding sites AGR2 S1–S4 and AGR3 S1
were transfected into DUCaP cells. The
renilla luciferase vector PGL4.73 served as
a transfection control. PGL3P vector
without an enhancer insert served as the
baseline control. One day after
transfection, cells were treated with either
1 nM R1881 or solvent for 24 h and were
thereafter processed for dual luciferase
assays. The firefly luciferase activity was
normalized to the renilla luciferase
transfection control activity and related to
the activity of the baseline control (Contr).
(B) To test the functionality of the AREs in
AR enhancer sequences AGR2S1 (two
putative AREs) and AGR3S1 (three
putative AREs), these elements were
mutated by site-directed mutagenesis and
the effect on androgen regulation was
assessed in the reporter gene assay.
Analysis and calculations were performed
identically to those in (A). Reporter gene
assay values represent the mean  SD of
three or four independent experiments.
Statistical differences were calculated
using Student’s t-test. *P < 0.05;
**P < 0.01; ***P < 0.001.
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PC3 cells were transfected with luciferase reporter vec-
tors containing the AGR2 S1 or AGR3 S1 enhancers
or their ARE mutated counterparts together with a
low (50 ng) or a high (250 ng) amount of an AR
expression vector or a control expression vector. The
results obtained confirmed the function of the enhanc-
ers and the putative AREs (Fig. 6). Furthermore,
although the synthetic androgen stimulated reporter
gene activity at lower and higher AR protein levels, E2
stimulated at the higher level only, thus confirming the
dependence on high AR protein levels for E2 induc-
tion. As expected, mutation of the most functional
AREs of both enhancers decreased hormone induced
reporter gene activities.
Histone modification and androgen-induced
chromatin remodelling of the regulatory
elements
Verification of AR-driven enhancer activity of AGR2
S1–4 and AGR3 S1 sequences lead us to investigate
other chromatin events present at these enhancers that
might cooperate with androgen regulation. Because
histone H3K4Me1 has been reported as one of the few
chromatin markers to be heavily enriched at cell type-
specific active enhancers [30], we used the ChIP-qPCR
assay to assess the presence of this marker on AGR
enhancers. The PSA enhancer (PSA E) was used as a
positive control (Fig. 7A). Strong histone H3K4Me1
enrichment (100–200-fold relative to an IgG precipi-
tated sample) was seen in all four AGR2 enhancers
without androgen stimulation. This represented an
enrichment that was two- to four-fold higher than that
seen for the PSA enhancer. The AGR3 enhancer
showed only minimal enrichment (four-fold), indicat-
ing a much less active chromatin status compared to
AGR2 enhancers. Androgen treatment generally had
little effect on the H3K4Me1 status of these enhancers.
Similar to the presence of H3K4Me1 at the enhanc-
ers, several genome-wide studies also showed the
enrichment of transcriptional coactivator histone acet-
ylase p300 at cell type-specific enhancers [30,31].
Because the recruitment of p300 to promoters and to
enhancers was reported to coordinate AR transactiva-
tion of the genes for PSA and KLK2 [32,33], we aimed
to determine whether it was also the case for the regu-
lation of AGR genes. Again, we used the ChIP-qPCR
assay to assess p300 enrichment to AGR enhancers
(Fig. 7B). P300 enrichment to the PSA enhancer was
confirmed. After 40 min of androgen treatment, five-
to six-fold higher p300 recruitment was seen at both
the AGR2 S1 and AGR2 S2 sites. The enrichment was
further increased for AGR2 S1 and peaked at 10-fold
after 4 h of treatment. The AGR2 S3 and AGR2 S4
sites also showed a minimum of two-fold p300 loading
after 40 min or 4 h of androgen treatment. Interest-
ingly, p300 enrichment to these AGR2 enhancers also
diminished to basal levels after 16 h of androgen treat-
ment in parallel to AR binding (Fig. 4D). At the
AGR3 S1 enhancer, p300 showed only a minimal
enrichment of 1.4-fold after 40 min and 4 h of andro-




























































































Fig. 6. AR-mediated oestrogen regulation of AGR2 and AGR3
enhancers. Firefly reporter vectors containing AGR2 S1 and AGR3
S1 sequences were transfected into PC-3 cells together with 0.05
or 0.25 lg AR expression vector to test the responsiveness of
reporter vectors to androgen and oestrogen. Renilla luciferase
reporter vector PGL4.73 was used as a transfection control. The
PSG5 vector without an insert served as a filling DNA. (A) Wild-
type AGR2 S1 (AGR2 wt) vector or the vector with mutation
inactivated ARE2 of AGR2 S1 fragment (AGR2 Mu; described in
the legend of Fig. 5) were used. One day after transfection, the
cells were treated either with 10 nM E2 or 1 nM R1881 for 24 h
and subsequently processed for dual luciferase assays. (B) Wild-
type AGR3 S1 (AGR3 wt) vector or the vector with mutation
inactivated ARE3 of the AGR3 S1 fragment (AGR3 Mu; described
in legend to Fig. 5) were transfected and hormone-treated as
described in (A). Firefly luciferase activity was normalized to renilla
luciferase activity and the regulation of hormone-treated samples
was calculated in relation to the solvent control (Contr)-treated
samples. Values represent mean  SD of two or three
independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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Previous studies on the PSA and KLK2 promoters
showed a direct looping interaction between the proxi-
mal and distal binding transcription factors in a single
complex. RNA Pol II has been observed to interact
with both the proximal promoter and the far upstream
enhancers of genes [3,33]. To determine whether such
an interaction is also important for androgen regula-
tion of AGR2 and AGR3, RNA Pol II binding to
their AR enhancers was analyzed by Pol II-ChIP and
a region close to the AGR2 proximal promoter (AGR2
Pr, +50/+137) was used as a positive control (Fig. 7C).
As expected, after 40 min of androgen treatment, there
was a two-fold higher RNA Pol II recruitment to the
AGR2 proximal promoter to initiate transactivation.
With time, Pol II was enriched further and remained
at the proximal promoter until 16 h, when the experi-
ment was terminated. The AGR2 S3 enhancer was
maximally loaded four-fold by RNA Pol II after 4 h
of treatment. A lower level (up to two-fold) of recruit-
ment of RNA Pol II was seen for the AGR2 S1, S2
and S4 enhancers. Unlike the sustaining strong recruit-
ment of RNA Pol II to the AGR2 proximal promoter
after 16 h, enrichment to the AR enhancers of AGR2
was already diminished at this time. These results indi-
cate that, although far away from the transcription
start site, the AR enhancers in AGR2 were brought
into proximity with the proximal promoter through
the formation of the transcription complex and the
bridging of RNA Pol II. Interestingly, significant
androgen induced Pol II recruitment could not be seen
at the AGR3 S1 enhancer site, which is just 1 kb
downstream of the TSS, indicating a mechanism that
differs from the formation of a looped structure.
Discussion
Previous studies have reported androgen and oestrogen
regulation of AGR2 expression in prostate and breast
cancer cells [10–12,15]; however, the detailed mecha-
nism, as well as the regulation of its close homologue
AGR3, remains unknown. The present study per-
formed in AR positive cell lines consistently showed
androgen regulation of AGR2 and AGR3 expression.
Besides regulation by androgens, we also observed an
E2 response and established the underlying mechanism.
The effect of E2 was found not to be mediated via the
ER but through AR activation at concentrations
 5 nM in conjunction with a high AR level. This
pattern of hormone activation is not unique for AGR2
and AGR3 but was also confirmed for the well-charac-
terized androgen-regulated gene FKBP5 in DUCaP
and VCaP PCa cells. Oestrogen was previously
reported to induce the expression of androgen-respon-
sive genes, such as the genes for PSA, KLK2 or
NKX3.1 in LNCaP cells [9,34], via the promiscuous,
mutated AR-V877A that these cells harbour. There-
fore, we focused on steroid hormone regulation in
DUCaP and VCaP cells that both express wild-type
AR [23]. Overexpression of AR coactivator ARA70 or
co-stimulation with sex hormone-binding globulin has
also been reported to mediate E2-induced AR tran-
scriptional activity [35,36]. In the present study, E2
alone (and none of the ER agonists that we tested)
could induce androgen-regulated genes in DUCaP
























































































































Fig. 7. AR binding sites in the AGR genes are located within active
chromatin regions and androgen induces the recruitment of
cofactors and RNA poymerase II. ChIP-qPCR was used to analyze
the enrichment of the active chromatin histone marker H3K4Me1
(A), the transcriptional coactivator histone acetyl-transferase p300
(B) and RNA Pol II (C) on the AR binding sites of the AGR2 and
AGR3 genes in cells treated with 1 nM R1881 for the time points
indicated. The PSA 4-kb enhancer served as a positive control. The
ChIP-qPCR analysis was performed as described in the legend to
Fig. 3D. The enrichment of H3K4Me1 was normalized to control
IgG precipitated DNA (A). Androgen stimulated p300 and RNA
Pol II enrichment to the enhancers was normalized to the control
solvent-treated samples (B, C). The AGR2 proximal promoter
region (AGR2 Pr) was used as a positive control for RNA Pol II
binding. The histograms represent the mean  SD of three or four
independent experiments. Statistical differences were calculated
using Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
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reporting that E2 (but not any other synthetic oestro-
gen agonist) can bind AR at super-physiological con-
centrations and is able to induce AR transcriptional
activity [35].
Oestrogen induction of AGR2 was previously studied
in breast cancer cells. The induction by E2 reported for
that cell type is weak compared to the robust effects
observed in the PCa cell lines in the present study. In
MCF-7, LCC9 and ZR-75-1 cells, E2 induced AGR2 by
two-fold or less at the mRNA or protein level [11,15]
and a luciferase reporter gene construct employing the
proximal 1594 to 94 bp promoter also showed only
a two-fold induction of reporter gene [15]. An enhanced
AGR2 induction was obtained with a combination of
E2 and the anti-oestrogen tamoxifen, raising the ques-
tion of whether this is a classical ER regulation.
The findings of the present study also raise the ques-
tion of whether oestrogen regulation of androgen-
responsive genes via AR is a general pattern for tumour
cells that express a high level of wild-type AR. The
overexpression of AR alone in PC-3 cells to a level simi-
lar to that endogenously expressed in DUCaP cells was
sufficient to trigger oestrogen regulation of androgen-
responsive reporter gene expression, confirming the
hypothesis that a high level of AR in DUCaP cells
mediates oestrogen regulation. In agreement with these
results, the same pattern of androgen and oestrogen
regulation was confirmed in VCaP cells that also
express a high level of wild-type AR. Prostate cancer
cell lines with lower AR expression levels often harbour
mutant promiscuous ARs that respond to oestrogens
and other steroid hormones at lower concentrations,
such as LNCaP or 22RV1 cells [37,38]. The results of
the present study are in line with other studies reporting
that increased AR expression could sensitize cells to
low levels of androgen, as well as change the agonist
spectrum [39,40]. There is accumulating evidence that
AR is overexpressed in a vast majority of prostate
tumours that relapse after hormone ablation treatment
[41] and alteration of the AR pathway has been found
in 56% of primary tumours and 100% of tumour
metastases [42]. Because there is residual androgen in
prostate tissue of patients under androgen ablation
therapy [43], activation of overexpressed AR by resid-
ual androgens and promiscuous activation by other ste-
roid ligands is considered to be one of the major
therapy escape mechanisms [44]. In this context, the
results of the present study suggest that oestrogens
might support AR activation in this situation.
Both AGR2 and AGR3 were characterized as pri-
mary responsive genes of AR in PCa cells [45], provid-
ing additional models for studying the mechanism of
AR regulation. In concordance with other reports
showing that a majority of the AR regulatory
sequences are located outside the proximity promoters
[46], our ChIP-seq analysis identified several AR bind-
ing and functionally active sites of the two genes, in
the distal promoter and the first intron, respectively. A
rapid AR loading of all these enhancers after
5–10 min of androgen treatment was observed and, as
in the case of the PSA and KLK2 enhancers [33,34],
the AR enrichment peaked at approximately 1 h and
diminished thereafter, indicating a transient transcrip-
tion complex recruitment.
In an attempt to characterize chromatin remodelling
at the enhancers that coordinated androgen regulation
of AGRs, active enhancer markers H3K4Me1 and
p300 were chosen [30,31,47]. We found that all four
AGR2 enhancers are highly occupied with the
H3K4Me1 marker, whereas the AGR3 enhancer
yielded 50-fold less enrichment. This indicates a less
active chromatin status of AGR3, which corresponds
with a much lower basal expression level of the AGR3
compared to AGR2. Androgen also induced the
recruitment of p300 to the AR binding sites of AGR2
but not to AGR3 enhancers. p300 enhances transcrip-
tion by recruitment of additional activating factors
and through its acetyltransferase activity. For the gene
AGR3, this function appears to be exerted by other
histone-modifying enzymes and/or cofactors.
Despite the close proximity of the AGR2 and AGR3
genes on chromosome 7p21 and androgen-responsive
enhancers in both genes, their expression, especially at
the protein level, is distinct and variable in different
PCa cell lines. AGR3 protein, for example, is
expressed at a significant level only in VCaP cells and
at a very low level in DUCaP cells, whereas, in all
other PCa cell lines investigated, AGR3 protein was
not visible in western blot analysis. By contrast,
AGR2 protein was detected, although at various lev-
els, in several PCa cell lines [10]. The relative mRNA
levels parallel the protein abundance in the different
cell lines. Uncoupled expression of AGR2 and AGR3
proteins was also found in different ovarian cancer
cells [21]. In prostate tissue, AGR2 protein is elevated
in PCa cells, especially in low grade tumours and dis-
plays a rather uniform expression pattern [10]. By con-
trast, the expression of AGR3 in primary prostate
tumours is highly heterogeneous, with high protein lev-
els in a small fraction of tumour cells among a major-
ity of AGR3 negative cells (G Schäfer, ACB Cato &
H Klocker unpublished results). This somehow mirrors
the black and white picture of AGR3 expression seen
in the cell lines.
The discordant expression pattern suggests that addi-
tional factors and cell type-specific effects modulate
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the expression of AGR2 and AGR3. At the protein
level, the two AGR subtypes can be aligned for
approximately 94% of their sequence with a maximal
identity of 65%. A bioinformatics comparison of the
whole gene sequences, including 20 kb of the upstream
sequence, revealed that 100% of the sequence length
can be aligned with 47% sequence identity and 29% of
the alignment consisting of gaps. Given these data, the
relationship between AGR2 and AGR3 appears rather
distant on the protein, as well as the DNA level, which
suggests a potential gene duplication event far back in
time. The regulatory differences between AGR2 and
AGR3 as described in the present study and by Gray
et al. [21] are not only attributable to the different num-
bers and locations of the active AREs, but also have to
be interpreted in the light of the proximal transcription
factor binding site profiles, which can work as ‘docking
stations’ to recruit the distal co-activators. We calcu-
lated the differential profile for 5 kb upstream of both
promoters using STRAP (http://www.ncbi.nlm.nih.gov/
pubmed/20127973) and found more than 50 transcrip-
tion factor matrices with a P-value difference >1 order
of magnitude.
The finding that AR regulatory elements function as
distal enhancers rather than proximal promoters is not
unique to the AGR2 gene, and is also seen in the
androgen regulation of PSA and TMPRSS2 [3,46]. In
the well studied model of the gene for PSA, AR binds
to AREs both in the proximal promoter and in the
4-kb distal enhancer region, and both sites interact
with each other through a common RNA Pol II-con-
taining AR transcription complex [3]. This model of
communication between distant AR enhancers and the
proximal promoter is also seen in the present study of
the AGR2 gene, with the difference that there are four
AR regulatory enhancers instead of one, and also that
there is no binding site in the proximal promoter. This
implies that transcription factors binding within the
proximal promoter work as docking molecules to
recruit the distal AR-containing coactivator complexes
and RNA Pol II to assemble the transcriptional
machinery on the proximal promoter. Candidate fac-
tors are the forkhead transcription factors, FoxA1-3,
and Ets transcription factor, SPDEF, all of which were
reported to regulate AGR2 expression [48,49]. Putative
transcription factor binding sites were identified in sil-
ico in the proximal promoter at 46/30 for Ets and
at +8/+28 for forkhead proteins.
The direct interaction between the distal AREs and
the proximal promoter involving RNA Pol II does not
appear to be the only model for androgen regulation
because RNA Pol II occupancy does not mirror the
loading of AR in the FKBP5 gene, where the AR enh-
ancers are located in the fifth and sixth introns more
than 60 kb downstream of the TSS [27,50]. A similar
situation can be seen in AGR3 transactivation, with the
functional ARE located 1 kb downstream of the TSS in
the first intron. It is not known yet whether a loop
structure could be applied only to genes with regulatory
elements upstream of the TSS. Further efforts are
required aiming to determine the mechanism of andro-
gen regulation with enhancers downstream of the TSS.
In conclusion, our characterization of the androgen
regulation of AGR2 and AGR3 provides additional
models for studying androgen and AR with respect to
gene regulation, as well as in prostate carcinogenesis
and tumour progression, and provides evidence for




Reagents and steroid hormones were obtained from Sigma
Aldrich (St Louis, MO, USA) unless otherwise indicated.
For western blotting, the antibodies used were: AGR2
(ab43043; Abcam, Cambridge, UK), AGR3 (ab82400; Ab-
cam), aTubulin (sc-8035; Santa Cruz Biotechnologies,
Santa Cruz, CA, USA), AR (MU256-UC; Biogenex, San
Ramon, CA, USA), GAPDH (CH-MAB374; Chemicon,
Temecula, CA, USA), IRDye800-conjugated goat anti-
mouse (611-132-122; Rockland, Gilbertsville, PA, USA)
and Alexa Fluor 680-conjugated goat anti-mouse (a21058;
Invitrogen, Carlsbad, CA, USA). For ChIP, the antibodies
employed were: AR (3202; Cell Signaling, Danvers, MA,
USA; UB 06-680; Millipore, Billerica, MA, USA),
H3K4Me1 (ab8895; Abcam), p300 (sc-585 X; Santa Cruz
Biotechnology), RNA Pol II (sc-899 X; Santa Cruz Bio-
technology) and normal rabbit IgG (sc-2027; Santa Cruz
Biotechnology). The synthetic androgen R1881 was pur-
chased from New England Biolabs (Ipswich, MA, USA),
oestradiol and ICI 182780 from Tocris (Bristol, UK), and
ER agonists and AR antagonists from Sigma-Aldrich.
Nanofectin siRNA was purchased from PAA (Paching,
Austria), Lipofectamine 2000 was obtained from Invitro-
gen, proteinase K from Roche (Basel, Switzerland), protein
A sepharose beads from GE Healthcare (Upsala, Sweden),
and primers and siRNAs from GenXpress (Vienna, Aus-
tria) or Applied Biosystems (Foster City, CA, USA).
Cell culture and transfection
Human PCa cell lines LNCaP, 22Rv1, VCaP and PC-3 were
obtained from ATCC (Manassas, VA, USA). DUCaP was a
generous gift from Dr Jack Schalken (Center for Molecular
Life Science, Nijmegen, The Netherlands). DUCaP and
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VCaP cells were originally derived from different metastasis
tissues of the same patient with hormone refractory PCa
and shared similar molecular characterization, such as a
high level of wild-type AR, low PSA expression and p53
mutation [23,51,52]. For routine culture, the cells except
VCaP were maintained in RPMI 1640 (PAA) supplemented
with 10% fetal bovine serum (PAA) and 2 mM L-glutamine
(Invitrogen). VCaP cells were cultured in DMEM low glu-
cose medium (PAA), supplemented with 10% fetal bovine
serum, 2 mM L-glutamine and 1.4 mgmL1 D-glucose. For
steroid hormone treatment, cells were seeded in phenol-red
free RPMI 1640 (Fischer, Logan, UT, USA) supplemented
with 5% (LNCaP and 22Rv1) or 10% (DUCaP, VCaP)
charcoal/dextran-treated fetal calf serum (Fischer) for up to
3 days before incubation with the indicated reagent at the
stated concentration and duration.
Semi-confluent DUCaP and LNCaP cells were transfect-
ed with 20 nM siRNA for 48 h or plasmid DNA for 24 h
using the Nanofectin siRNA kit (PAA) or Lipofectamine
2000 (Invitrogen) in accordance with the manufacturer’s
instructions. Next, the cells were treated with either R1881
or E2 at the indicated concentrations and durations. The
target sequences of the siRNAs were 5′-GACCUACCGAG
GAGCUUUC-3′ for the AR transcriptional start region
and 5′-GCACUGCUACUCUUCAGCA-3′ for the AR
LBD region. Luciferase siRNA was used as a control.
RNA isolation, cDNA synthesis and real-time
qPCR
RNA isolation, cDNA synthesis and qPCR were performed
as described previously [10]. qPCR using cDNA or ChIP-
isolated DNA as a template was carried out using SYBR
Green chemistry or a Fam-labelled Taqman probe detec-
tion on an ABI 7500 Fast machine (Applied Biosystems).
Forty amplification cycles were performed with denatur-
ation at 95 °C for 15 s, followed by annealing and
extension at 60 °C for 1 min. The FKBP5 primers and
Taqman probe (Hs01561006_m1) were obtained from
Applied Biosystems; other primers were self-designed and
the sequences are given in Tables 2 and 3.
Western blotting
Western blotting of total cell extracts normalized for pro-
tein content via the Bradford assay (Bio-Rad Laboratories,
Hercules, CA, USA) was performed as described previously
[10]. Primary antibodies were incubated overnight at 4 °C in
0.2% Tween-20 in NaCl/Pi at the concentrations: AGR2
(dilution 1 : 1000), AGR3 (dilution 1 : 1000), aTubulin
(dilution 1 : 10 000), AR (dilution 1 : 100) and GAPDH
(dilution 1 : 100 000). After washing, membranes were
incubated with fluorophore-conjugated secondary antibod-
ies (dilution 1 : 5000) before signal detection using the
Odyssey system (LiCor Biosciences, Lincoln, NE, USA).
ChIP-sequencing and PCR
Chromatin immunoprecipitation was performed as
described previously [32]. In brief, DUCaP cells were trea-
ted with 1 nM R1881, 10 nM E2 or vehicle equivalent for
1 h before formaldehyde cross-linking, DNA sonication
and immunoprecipitation with two combined AR antibod-
ies, or antibodies against H3K4Me1, p300 or RNA Pol II.
Normal rabbit IgG was used as a control. After pulling
down the antibody–protein–DNA complex using protein A
sepharose beads, the complex was digested and reverse
cross-linked with 500 lgmL1 proteinase K by shaking at
56 °C overnight. DNA was purified with ChIP DNA kit
(Zymo Research, Irvine, CA, USA) and eluted in 25 lL of
elution buffer.
ChIP AR-precipitated DNA samples were used either for
deep sequencing or PCR amplification. Preparation of the
libraries and sequencing were performed using the Solexa
Table 3. Primer sequences for amplification of AR binding sites in the AGR genes.





PSA enhancer F: GGGGTTTGTGCCACTGGTGAG 4 kb promoter 65 366
Positive control R: GGGAGGCAATTCTCCATGGTTC
AGR2 enhancer S1 F: TGAGGCCCGTTTTACCTACTT 11 kb promoter 60 171
S1 R: AAGAGGCAAAGTGAGTGACGA
S2 F: AGGGTCAGACTCGAACTGCT 5.5 kb promoter 60 154
S2 R: TTCCATCGAAATGATATGCTG
S3 F: CAAAGTGAAAATGGCCACAA 8 kb promoter 60 148
S3 R: GTGGCATCTTGTCACCTGAA




AGR2 Pr F: GCAGCACTAGTGGGTGGGATTG Transcription start site 60 87
AGR2 Pr R: GATGCGGTCCAAGCTTCTG
AGR3 enhancer F: CCTGGGTTGAGCTTTGTGTT Intron 1 60 239
R: CCCTCCTTTCCTGTCCTTTC
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sequencing platform (GAII analyzer; Illumina, San Diego,
CA, USA) in accordance with the manufacturer’s instruc-
tions. Briefly, ChIP-DNA was end-repaired, adaptor ligated
and PCR amplified, followed by cluster generation and
sequencing-by-synthesis using the Genome Analyzer (Illu-
mina). ChIP-DNAs were also subjected to amplification by
either 40 cycles of normal PCR or real-time PCR using prim-
ers targeting ChIP-seq identified AR binding fragments of
the AGR2 and AGR3 genes (Table 3). The PSA enhancer
region 4 kb upstream of the transcriptional start site was
used as a positive control. PCR products were separated on a
2% agarose gel and visualized by staining with SYBR Green
(dilution 1 : 5000; Fisher Scientific, Vienna, Austria).
Bioinformatics analysis
Raw sequencing data were analyzed using PIPELINE analysis
software (Illumina), bases were called by Bustard and
aligned to the unmasked human reference genome (NCBI
v36, hg18) using BOWTIE [53]. All reads that could be
mapped to multiple locations in the human genome, such
as repetitive elements, were discarded. The MACS tool was
used to identify AR-enriched regions in a genome-wide
manner [54]. Read-data were visualized using a local instal-
lation of the GENERIC GENOME BROWSER (http://promotion.
molgen.mpg.de/gb2/gbrowse/human/).
Reporter vector construction and site-directed
mutagenesis
AR bound enhancer fragments of AGR2 and AGR3 were
PCR amplified with the primers listed in Table 2 using
Phusion high fidelity DNA polymerase (Finnzyme, Espoo,
Finland) and inserted into the pSC-B entry vector (Strata-
gene, La Jolla, CA, US). Inserts were size verified by KpnI
and SacI restriction and sequencing, followed by ligation
into a PGL3 promoter plasmid (Promega, Madison, WI,
USA) using the Rapid DNA Ligation Kit (Roche) to gen-
erate firefly luciferase reporter vectors. Putative AREs were
deleted using the QuikChange II Site-Directed Mutagenesis
Kit (Stratagene). The mutagenic primers used were 5′-
gctgAGCACAggaCACCGAgggaatggtgc-3′ and 5′-ggagtcA
GGACAagcCACTCCtgctgaagtag-3′ for AGR2 S1 ARE1
(AGCACAggaTGCTGA) and ARE2 (AGGACAagcTGAT
CC), respectively, and 5′-ctgggtTGAGCTttgTTTGTCagag
tcaactgtccc-3′, 5′-ccagagtCAACTGtccGTCGCCtgtactaaaatc
cacc-3′ and 5′-cagtctttaaAGTCTCagaTGACCAaggccttaagg-
tac-3′ for AGR3 S1 ARE1–3 (TGAGCTttgTGTTCC, CA-
ACTGtccCTGTCC and AGTACAagaTGACCA).
Luciferase reporter gene assay
Cells were seeded in 10% charcoal/dextran-treated fetal calf
serum at a density of approximately 50% confluence 24 h
before transfection. For DUCaP transfection, cells were
transfected with firefly luciferase reporter or site-directed
mutagenic vectors. PGL3 promoter plasmid without insert
was used as a control. For transfection of PC-3 cells, increas-
ing amounts of AR expression vector PSG5-AR (0, 0.001,
0.01, 0.05 and 0.25 lg) were transfected together with andro-
gen-responsive firefly reporter vector ARE2-PGL3B or
AGR2 and AGR3 reporter vectors. PSG5 vector without
insert was used as a filling vector. PGL4.73, an SV40 enhan-
cer/promoter-driven renilla luciferase reporter vector (Pro-
mega), was used as a transfection control. Twenty-four hours
after transfection, cells were treated with R1881 or E2 at the
concentrations indicated for 24 h, followed by cell lysis and
processing for quantification of luciferase activity using the
Dual Luciferase Reporter Assay kit (Promega). Firefly lucif-
erase activity was normalized to renilla luciferase activity.
Statistical analysis
Numerical data are presented as the mean  SEM of at
least two or three independent experiments. Statistical dif-
ferences were calculated using Student’s t-test. P < 0.05
was considered statistically significant.
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